The BsAb has more potent anti-tumor activity than combination therapy of the two parental mAbs and shows efficacy in tumors which are resistant to EGFR monotherapy and was amenable to combination therapy with tyrosine kinase inhibitors. This evidence concerns the gene EGFR and neoplasm.